Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31, 2026
Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
Regulatory News:
Median Technologies (Paris:ALMDT):
|
Total number of shares |
49,071,263 |
|
Number of real voting rights* (excluding treasury shares**) |
49,011,540 |
|
Theoretical number of voting rights* (including treasury shares**) |
49,048,063 |
|
(*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations |
|
Furthermore, as of July 31, 2026, out of the 14,424,541 warrants (BSA) issued in connection with the 2025 capital increase, 12,261,125 remained outstanding and exercisable.
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260810503229/en/
Median Technologies Emmanuelle Leygues VP, Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com
Investors – SEITOSEI ACTIFIN Ghislaine Gasparetto +33 6 85 36 76 81 ghislaine.gasparetto@seitosei-actifin.com
Press – MAARC Bruno Arabian +33 6 87 88 47 26 bruno.arabian@maarc.fr